Literature DB >> 22222338

Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients.

Roneka L Ravenell1, Diane L Kamen, J David Spence, Bruce W Hollis, Thomas J Fleury, Michael G Janech, Jonas S Almeida, Stephanie R Shaftman, Jim C Oates.   

Abstract

The ultimate goal is to identify and target modifiable risk factors that will reduce major cardiovascular events in African American lupus patients. As a first step toward achieving this goal, this study was designed to explore risk factor models of preclinical atherosclerosis in a predominantly African American group of patients with systemic lupus erythematosus (SLE) using variables historically associated with endothelial function in nonlupus populations. Fifty-one subjects with SLE but without a history of clinical cardiovascular events were enrolled. At entry, a Framingham risk factor history and medication list were recorded. Sera and plasma samples were analyzed for lipids, lupus activity markers and total 25-hydroxyvitamin D (25 OH)D) levels. Carotid ultrasound measurements were performed to determine total plaque area (TPA) in both carotids. Cases had TPA values above age-matched controls from a vascular prevention clinic population. Logistic regression and machine learning analyses were performed to create predictive models. 25(OH)D levels were significantly lower, and SLE disease duration was significantly higher in cases. 25(OH)D levels inversely correlated with age-adjusted TPA. Angiotensin-converting enzyme (ACE) inhibitor nonuse associated with case status. Logistic regression models containing ACE inhibitor use, 25(OH)D levels and low-density lipoprotein levels had a diagnostic accuracy of 84% for predicting accelerated atherosclerosis. Similar results were obtained with machine learning models, but hydroxychlo-roquine use associated with controls in these models. This is the first study to demonstrate an association between atherosclerotic burden and 25(OH)D insufficiency or ACE inhibitor nonuse in lupus patients. These findings provide strong rationale for the study of ACE inhibitors and vitamin D replenishment as preventive therapies in this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222338      PMCID: PMC3323721          DOI: 10.1097/MAJ.0b013e31823fa7d9

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  26 in total

1.  The SLICC/ACR damage index: progress report and experience in the field.

Authors:  D D Gladman; M B Urowitz
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis.

Authors:  Georg Nickenig; David G Harrison
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

Review 3.  Predictive non-linear modeling of complex data by artificial neural networks.

Authors:  Jonas S Almeida
Journal:  Curr Opin Biotechnol       Date:  2002-02       Impact factor: 9.740

4.  Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D.

Authors:  B W Hollis
Journal:  Clin Chem       Date:  2000-10       Impact factor: 8.327

5.  Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy.

Authors:  J David Spence; Michael Eliasziw; Maria DiCicco; Daniel G Hackam; Ramzy Galil; Tara Lohmann
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

Review 6.  Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis.

Authors:  Chi Chiu Mok; Daniel J Birmingham; Hoi Wah Leung; Lee A Hebert; Huijuan Song; Brad H Rovin
Journal:  Rheumatology (Oxford)       Date:  2011-06-29       Impact factor: 7.580

7.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.

Authors:  G B Mancini; G C Henry; C Macaya; B J O'Neill; A L Pucillo; R G Carere; T J Wargovich; H Mudra; T F Lüscher; M I Klibaner; H E Haber; A C Uprichard; C J Pepine; B Pitt
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

Review 8.  Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease.

Authors:  J David Spence
Journal:  Am J Cardiol       Date:  2002-02-21       Impact factor: 2.778

9.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

Review 10.  Endothelial function, inflammation, and prognosis in cardiovascular disease.

Authors:  Manuel A Gonzalez; Andrew P Selwyn
Journal:  Am J Med       Date:  2003-12-08       Impact factor: 4.965

View more
  24 in total

1.  Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients.

Authors:  Susana Mellor-Pita; Pablo Tutor-Ureta; Silvia Rosado; Khusama Alkadi; Fernando Granado; Carlos Jimenez-Ortiz; Raquel Castejon
Journal:  Clin Rheumatol       Date:  2019-01-09       Impact factor: 2.980

2.  Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Safia Ogbi; Takayuki Matsumoto; R Clinton Webb
Journal:  Pharmacol Res       Date:  2016-09-14       Impact factor: 7.658

Review 3.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

Review 4.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

Review 5.  Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.

Authors:  Lisa N Guo; Vinod E Nambudiri
Journal:  Clin Rheumatol       Date:  2020-07-05       Impact factor: 2.980

6.  Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Hong Fang; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-08-16       Impact factor: 7.580

7.  A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients.

Authors:  Diane L Kamen; Jim C Oates
Journal:  Am J Med Sci       Date:  2015-10       Impact factor: 2.378

Review 8.  Atherosclerosis in systemic lupus erythematosus.

Authors:  George Stojan; Michelle Petri
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

Review 9.  Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus.

Authors:  Carol M Greco; Claire Nakajima; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

10.  ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  Jim C Oates; Viswanathan Ramakrishnan; Paul J Nietert; J David Spence; Thomas W Fleury; Margaret Markiewicz; Dayvia L Russell; Maria F Lopes-Virella
Journal:  Trans Am Clin Climatol Assoc       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.